The Tectonic Therapeutic, Inc. (NASDAQ: TECX) SEC filings page brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tectonic is a clinical-stage biotechnology company focused on GPCR-targeted biologic medicines, and its filings provide structured insight into financial results, clinical development updates and corporate events.
Investors can use this page to access Form 10‑Q and Form 10‑K reports, which contain detailed discussions of Tectonic’s research and development activities, risk factors, and financial statements. For a company advancing programs such as TX45 in Group 2 pulmonary hypertension and PH‑ILD, and TX2100 for Hereditary Hemorrhagic Telangiectasia, these periodic reports explain how clinical trial progress and pipeline strategy relate to operating expenses and liquidity.
The page also surfaces Form 8‑K current reports, where Tectonic discloses material events such as quarterly financial results, positive topline clinical data, updated corporate presentations, and other significant announcements. These filings often reference attached press releases and slide decks that elaborate on trial designs, endpoints, and topline outcomes.
In addition, users can review Section 16 filings such as Form 4, which report changes in beneficial ownership by directors, officers, and other insiders, as well as proxy materials that discuss governance and executive compensation. Stock Titan’s platform layers AI-powered summaries on top of these documents to highlight key points, explain technical language, and help readers quickly understand the implications of lengthy filings without replacing the underlying source documents.
Together, the TECX SEC filings and AI summaries give a structured view of how Tectonic communicates its financial condition, clinical-stage risks, and strategic focus on GPCR-targeted biologics to regulators and investors.
Tectonic Therapeutic, Inc. Chief Financial Officer Daniel Lochner had 520 common shares withheld by the issuer on September 25, 2026, to satisfy tax-withholding obligations tied to restricted stock unit vesting and settlement. The reported price was $23.67 per share, and his direct holdings afterward were 58,024 shares. No Rule 10b5-1 plan is reported.
Tectonic Therapeutic, Inc. (TECX) Chief Scientific Officer Peter McNamara reported selling 536 shares on September 30, 2026, at a weighted average price of $23.04 per share; the shares sold in transactions ranging from $22.61 to $23.32. The sale was made under a Rule 10b5-1 trading plan adopted November 14, 2025. On September 25, 2026, the issuer withheld 444 shares to satisfy his tax withholding obligations from vesting and settlement of restricted stock units granted September 25, 2025; the reported transaction price was $23.67 per share.
Tectonic Therapeutic, Inc. Chief Medical Officer Marcella K. Ruddy had 525 common shares withheld by the issuer on September 25, 2026, to satisfy tax-withholding obligations tied to the vesting and settlement of restricted stock units granted September 25, 2025. The reported price was $23.67 per share; she directly held 67,157 shares after the transaction.
Tectonic Therapeutic, Inc. (TECX) reported that CEO Alise Reicin had 1,545 common shares withheld by the issuer on September 25, 2026, to satisfy tax-withholding obligations connected with vesting and settlement of restricted stock units granted on September 25, 2025. The reported price was $23.67 per share. After the transaction, her reported direct holdings were 309,078 common shares. As of September 25, 2026, the Reicin-Boiarsky Family Trust held 127,030 common shares.
Tectonic Therapeutic, Inc. Chief Business Officer Marc Schwabish had 411 shares withheld by the issuer on September 25, 2026, to satisfy tax-withholding obligations tied to vesting and settlement of restricted stock units granted on September 25, 2025. He directly held 44,903 shares following the transaction; the reported price was $23.67 per share.
Tectonic Therapeutic, Inc. (TECX) officer Peter McNamara gave notice of a proposed sale of 493 common shares, with an aggregate market value of $11,506.62. Morgan Stanley Smith Barney LLC is listed as broker, and September 30, 2026 is the approximate sale date. The shares are listed as acquired from the issuer through restricted stock units on September 25, 2026. The past-three-months section lists 10b5-1 sales of 43 shares on August 12, 2026, for $1,505.00, and 43 shares on August 25, 2026, for $1,570.36.
Tectonic Therapeutic, Inc. (TECX) announced favorable topline safety, tolerability and pharmacokinetic results for TX2100 in its Phase 1a trial in healthy volunteers and said the study met its primary objectives. Detailed safety, tolerability, pharmacokinetic and anti-drug antibody results are to be presented at the CureHHT conference October 12–16, 2026.
The FDA granted TX2100 Fast Track Designation for HHT in September 2026, after clearing the company’s IND application in August 2026 for a U.S. Phase 1b trial. Two HHT patient studies are planned to run in parallel: an open-label Phase 1b trial in patients dependent on hematologic support, anticipated to start by year-end 2026, and a placebo-controlled Phase 2 trial in moderate-to-severe HHT patients, anticipated to start in early 2027. Phase 1b endpoints explore iron and red blood cell support needs and hematologic parameters; Phase 2 endpoints are expected to include epistaxis, hemoglobin and hematologic support.
Tectonic Therapeutic, Inc. (TECX) reported that Chief Business Officer Marc Schwabish received a grant of 17,750 employee stock options on September 3, 2026. The options have an exercise price of $29.92 per share, expire on September 2, 2036, and cover 17,750 shares of common stock.
According to the vesting terms, 1/8 of the options vest on September 3, 2026, with the remaining options vesting in 42 equal monthly installments beginning October 3, 2026, subject to his continued service to the company on each vesting date. No Rule 10b5-1 trading plan is reported.
Tectonic Therapeutic, Inc. (TECX) reported that Chief Scientific Officer Peter McNamara received a grant of stock options for 21,000 shares of common stock on September 3, 2026. The options have an exercise price of $29.92 per share and expire on September 2, 2036. One-eighth of the options vest on September 3, 2026, with the remainder vesting in 42 equal monthly installments beginning October 3, 2026, subject to his continued service. No transactions were made under a Rule 10b5-1 trading plan, and McNamara now holds 21,000 options directly from this award.
Tectonic Therapeutic, Inc. (TECX) reported that Chief Financial Officer Daniel Lochner received a grant of 24,250 employee stock options on September 3, 2026. The options have an exercise price of $29.92 per share and expire on September 2, 2036. According to the vesting terms, 1/8 vests on September 3, 2026, with the remaining shares vesting in 42 equal monthly installments beginning October 3, 2026, subject to his continued service.